TY - JOUR TI - PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade AU - Peng, Qi AU - Qiu, Xiangyan AU - Zhang, Zihan AU - Zhang, Silin AU - Zhang, Yuanyuan AU - Liang, Yong AU - Guo, Jingya AU - Peng, Hua AU - Chen, Mingyi AU - Fu, Yang-Xin AU - Tang, Haidong T2 - Nature Communications AB - Immune checkpoint blockade therapies have shown clinical promise in a variety of cancers, but how tumor-infiltrating T cells are activated remains unclear. In this study, we explore the functions of PD-L1 on dendritic cells (DCs), which highly express PD-L1. We observe that PD-L1 on DC plays a critical role in limiting T cell responses. Type 1 conventional DCs are essential for PD-L1 blockade and they upregulate PD-L1 upon antigen uptake. Upregulation of PD-L1 on DC is mediated by type II interferon. While DCs are the major antigen presenting cells for cross-presenting tumor antigens to T cells, subsequent PD-L1 upregulation protects them from killing by cytotoxic T lymphocytes, yet dampens the antitumor responses. Blocking PD-L1 in established tumors promotes re-activation of tumor-infiltrating T cells for tumor control. Our study identifies a critical and dynamic role of PD-L1 on DC, which needs to be harnessed for better invigoration of antitumor immune responses. DA - 2020/09/24/ PY - 2020 DO - 10.1038/s41467-020-18570-x DP - www.nature.com VL - 11 IS - 1 SP - 4835 LA - en SN - 2041-1723 UR - https://www.nature.com/articles/s41467-020-18570-x Y2 - 2020/09/25/18:27:44 ER -